Plasma pTau217 as a marker of both the current and future state of amyloid pathology in adults with DS

Plasma pTau217 effectively predicts amyloid-PET positivity in individuals with DS and generates continuous estimates of time-to-amyloid-positivity in individuals with cortical amyloid burden > 30 CL. However, it is not as useful for estimating time-to-positivity at lower amyloid pathology levels (10 - 30 CL). This specific plasma pTau217 assay may lack sensitivity for detecting early amyloid positivity in people with DS.

Authors

Institutions

Publication Details

Journal
Alzheimer s & Dementia
Published
2025-12-01
DOI
https://doi.org/10.1002/alz70856_099356
Primary Topic
Down syndrome and intellectual disability research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Plasma pTau217 as a marker of both the current and future state of amyloid pathology in adults with DS

Ziqiao Jiao, Lauren T. Ptomey, Benjamin L. Handen, Sharon J. Krinsky‐McHale et al.
Alzheimer s & Dementia
Down syndrome and intellectual disability research
article

Plasma pTau217 as a marker of both the current and future state of amyloid pathology in adults with DS

Ziqiao Jiao, Lauren T. Ptomey, Benjamin L. Handen, Sharon J. Krinsky‐McHale, J. Lee, Christy Hom, Patrick J. Lao, Julie K. Wisch, Sigan L. Hartley, Zinayida Schlachetzki, Jeffrey Murray Burns, Florence Lai, Jordan P. Harp, Beau M. Ances, Shahid Zaman, Ira T. Lott, Bradley T Christian, Laura Ibanez, Adam Brickman, Ann D Cohen, Frederick A Schmitt, Elizabeth Head, Michael S. Rafii, Natalie C. Edwards, Mark Mapstone, H. Diana Rosas, Melissa Petersen
article en

Abstract

Plasma pTau217 effectively predicts amyloid-PET positivity in individuals with DS and generates continuous estimates of time-to-amyloid-positivity in individuals with cortical amyloid burden > 30 CL. However, it is not as useful for estimating time-to-positivity at lower amyloid pathology levels (10 - 30 CL). This specific plasma pTau217 assay may lack sensitivity for detecting early amyloid positivity in people with DS.

Alzheimer s & DementiaVol. 21(S2)
University of Southern California (US), University of North Texas (US), Autism Research Institute (US), University of Wisconsin–Madison (US), Harvard University (US), University of Kentucky (US), University of Kansas (US), University of North Texas Health Science Center (US), University of Pittsburgh (US), University of California, Irvine (US), Washington University in St. Louis (US), University of Cambridge (GB), Columbia University Irving Medical Center (US), New York State Office for People With Developmental Disabilities (US), Massachusetts General Hospital (US), University of Kansas Medical Center (US), Columbia University (US)
Reduced inequalities
Openalex Percentile: Top 27%
Down syndrome and intellectual disability research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.